No Data
Shareholder Li Shengyou and Huang Guijuan of Chengdu Kanghua Biological Products (300841.SZ) have completed their shareholding period, cumulatively reducing their holdings by 0.046 million shares.
Chengdu Kanghua Biological Products (300841.SZ) announced that the Shareholding plan of the company's Shareholders Li Shengyou and Huang Guijuan has expired, ...
Chengdu Kanghua Biological Products (300841.SZ): The phase III clinical trial approval notice for the six-valent Norovirus vaccine (Pichia pastoris) has been obtained.
Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris...
Chengdu Kanghua Biological Products (300841.SZ): Currently, the AI Siasun Robot&Automation Business has not been developed.
Glory Network reported on December 11 that Chengdu Kanghua Biological Products (300841.SZ) stated on the investor interaction platform that the company mainly engages in the research, production, and sales of human vaccines and has not yet started its Business in Siasun Robot&Automation.
Are Robust Financials Driving The Recent Rally In Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Stock?
Three shareholders of chengdu kanghua biological products (300841.SZ) plan to collectively reduce their shareholding by no more than 3.3%.
Chengdu Kanghua Biological Products (300841.SZ) announced that the company recently received notice from shareholders holding more than 5% of the shares, including Kangyue Qiming and other shareholders...
chengdu kanghua biological products (300841.SZ): The construction of the raw material workshop for ACYW135 meningococcal polysaccharide vaccine has been completed.
Gelonghui, November 6th: chengdu kanghua biological products (300841.SZ) stated on the investor interaction platform that the company has completed the construction of the ACYW135 group meningococcal polysaccharide vaccine raw liquid workshop and the "Kanghua biological vaccine production expansion project". They are currently in the supplementary application stage for pharmaceutical production permits, and production can begin after obtaining the production permit.
Is Weakness In Chengdu Kanghua Biological Products Co., Ltd. (SZSE:300841) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
